Fred Alger Management LLC Raises Position in Boston Scientific Corporation $BSX

Fred Alger Management LLC grew its position in Boston Scientific Corporation (NYSE:BSX) by 11.2% during the 4th quarter, Holdings Channel reports. The fund owned 1,096,675 shares of the medical equipment provider’s stock after buying an additional 110,728 shares during the quarter. Fred Alger Management LLC’s holdings in Boston Scientific were worth $104,568,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Claret Asset Management Corp boosted its holdings in shares of Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after acquiring an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 103 shares in the last quarter. Outfitters Financial LLC boosted its holdings in shares of Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after acquiring an additional 110 shares in the last quarter. Fayez Sarofim & Co boosted its holdings in shares of Boston Scientific by 2.1% in the third quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock valued at $520,000 after acquiring an additional 111 shares in the last quarter. Finally, Natural Investments LLC boosted its holdings in shares of Boston Scientific by 2.9% in the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after acquiring an additional 112 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.3%

BSX stock opened at $46.92 on Wednesday. The company has a market cap of $69.74 billion, a P/E ratio of 19.63, a P/E/G ratio of 0.89 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $45.99 and a 52 week high of $109.50. The company’s 50-day moving average price is $55.74 and its 200 day moving average price is $74.02. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BSX shares. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a report on Friday. UBS Group lowered their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Jefferies Financial Group lowered their target price on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Finally, Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $85.08.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.